Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). METHODS: 17DMAG was given intravenously over 1 hour daily for 5 days (schedule A) or daily for 3 days (schedule B) every 3 weeks. Plasma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ramanathan, Ramesh K., Egorin, Merrill J., Erlichman, Charles, Remick, Scot C., Ramalingam, Suresh S., Naret, Cynthia, Holleran, Julianne L., TenEyck, Cynthia J., Ivy, S. Percy, Belani, Chandra P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849772/
https://ncbi.nlm.nih.gov/pubmed/20177028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0415
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados